Cite
Data from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
MLA
Johanna C. Bendell, et al. Data from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.c.6530910.
APA
Johanna C. Bendell, Boris Kin Lin, Sophie Callies, Anna M. Szpurka, Gregory P. Donoho, Volker Wacheck, Wei Zhang, Susan C. Guba, Paul R. Sieber, Neal D. Shore, Costantine Albany, Ian D. Schnadig, David S. Morris, Oscar B. Goodman, Bryan A. Mehlhaff, Jennifer L. Cultrera, Sunil Babu, Ivor J. Percent, & Christopher J. Sweeney. (2023). Data from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. https://doi.org/10.1158/1078-0432.c.6530910
Chicago
Johanna C. Bendell, Boris Kin Lin, Sophie Callies, Anna M. Szpurka, Gregory P. Donoho, Volker Wacheck, Wei Zhang, et al. 2023. “Data from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer,” March. doi:10.1158/1078-0432.c.6530910.